Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform

Oppenheimer analyst Les Sulewski assumes coverage on Inova Technology, Inc. (NASDAQ: INVA) with a Outperform rating and a price target of $35.00.

The analyst comments "We assume coverage of Innoviva with an Outperform rating and $35 PT. We believe the market values INVA primarily as a declining respiratory royalty company while assigning limited credit to a fast-growing critical care and infectious disease platform and strategic healthcare assets. Durable Breo/Relvar and Anoro royalties fund IST growth, BD, strategic investments, and share repurchases. Xacduro and Giapreza lead current growth, while Zevtera, Nuzolvence, ex-US expansion, and potential acquisitions provide additional upside, in our view. We believe continued execution can shift investor perception from a royalty vehicle to a diversified specialty pharma platform."

For an analyst ratings summary and ratings history on Inova Technology, Inc. click here. For more ratings news on Inova Technology, Inc. click here.

Shares of Inova Technology, Inc. closed at $20.98 yesterday.

You May Also Be Interested In

• Fastly Inc. (FSLY) PT Lowered to $23 at DA Davidson Amid High Expectations
• KeyBanc on Darden Restaurants (DRI): 'Signs of Olive Garden Improvement Heading into Earnings'
• Ryanair says it will not add fuel surcharge despite rising costs